A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Times cited: 60
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal of Clinical Oncology.
Times cited: 395
Angiogenesis inhibitors in clinical development for lung cancer.
Seminars in Oncology.
Times cited: 51
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Advances in internal medicine.
Times cited: 9